Search

Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

Publication: Bill

Zhang, X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi. 2004. Persistent C-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Surgical management of scrotal lymphedema using local flaps

Publication: Bill

Halperin, T. J., S. A. Slavin, A. F. Olumi, and L. J. Borud. 2007. Surgical Management of Scrotal Lymphedema Using Local Flaps.

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)

Publication: Bill

Li, W., X. Zhang, and A. F. Olumi. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating C-Fos/C-Jun Heterodimers and Repressing C-FLIP(L).

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

Publication: Bill

Zhang, L., X. Zhang, G. W. Barrisford, and A. F. Olumi. 2007. Lexatumumab (TRAIL-Receptor 2 MAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model.

Search

Search results

Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer

Surgical management of scrotal lymphedema using local flaps

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer

Models of care and NCCN guideline adherence in very-low-risk prostate cancer

Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation

Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes